Kornimate/medical-research-clean huggingface dataset:
comparison of different methods of controlling pain during debonding of orthodontic brackets

Conditions: Analgesia; Orthodontic Appliance Complication

Summary: purpose of this study was to evaluate different methods of controlling pain during debonding

patients data was obtained from the department of orthodontics, armed forces institute of dentistry, rawalpindi. one hundred and ten patients were included in the study, which were divided into two groups, 55 patients in each group, based on method of controlling pain during debonding. to control pain during debonding in one group , teeth were stabilized with finger pressure with cotton between finger and teeth and then debonding using open mouth technique was done. in second group teeth were stabilized using a plastic wafer between maxillary and mandibular teeth and then debonding was done using closed mouth technique. in order to reduce biasness, all of the patients were debonded with same plier and with wires still ligated to brackets. with the help of vas, pain score was measured after debonding. a single operator performed complete procedure of debonding and pain recording.

Eligibility criteria:
inclusion criteria: patients between 13-21 years of age who can understand, assess, and answer the questionnaires. 2) no missing teeth except extracted premolars 3) undergoing upper and lower fixed orthodontic treatment with roth prescription 0.022-inch metal brackets . 4) finishing arch wires present for at least two months exclusion criteria: 1. the subjects with a previous history of facial or mandibular surgery or syndromes affecting the jaw or face . 2. patient with history of jaw sugeries. 3. patients with history of taking medicine periodically or in the last 24 hours (eg, painkillers, corticosteroids, and antiflu drugs), 4. patient with history of debonded brackets and replacement. 5. patient with history of tooth transplantation or microscrews placement.

Keywords: orthodontic pain
neugranin in breast cancer participants receiving doxorubicin/docetaxel

Conditions: Chemotherapy-induced Neutropenia

Summary: determination of the effect of neugranin on the duration and severity of severe neutropenia in participants receiving doxorubicin in combination with docetaxel.


Eligibility criteria:
inclusion criteria: * breast cancer participants scheduled to receive the at regimen (doxorubicin/ docetaxel) exclusion criteria: * participants may have received no more than 1 prior chemotherapy regimen (including adjuvant therapy if given within the last 12 months)
clinical study for the bongo device in the treatment of obstructive sleep apnea (osa)

Conditions: Obstructive Sleep Apnea

Summary: prospective, non-randomized, open label study

this study is a prospective, non-randomized, open label, single-center clinical study for the bongo nasal device for the treatment of obstructive sleep apnea. the study consists of two in laboratory polysomnographic studies and a one two week in home period.

Eligibility criteria:
inclusion criteria: * • capacity and willingness to sign informed consent * ≥ 21 years of age * diagnosis of mild to moderate osa (ahi ≥ 5 and ahi ≤ 30) within 12 months of the screening visit with the 3% hypopnea criteria * able to tolerate using the device during a day time trial/acclimation * are currently using cpap or have been prescribed cpap and are considered cpap non-adherent (as per either their cpap data card and/or verbal confirmation of a diagnosis and unwillingness to use cpap) exclusion criteria: * • nasal deformities * severe nasal allergies * rhinitis or moderate nasal congestion, acute upper respiratory (including nasal, sinus or middle ear) inflammation or infection, or perforation of the ear drum * co-morbid sleep disorders * currently on a hypnotic for insomnia (who have had insomnia for more than a month and take a hypnotic on a daily basis and/or transient insomnia being treated) * uncontrolled or serious illness, including but not limited to: severe breathing disorders including hypercapnic respiratory failure, respiratory muscle weakness, bullous lung disease (as seen in some types of emphysema), bypassed upper airway, pneumothorax, pneumomediastinum, etc.; severe heart disease (including heart failure); or pathologically low blood pressure. * full face mask user * mouth breather * pregnant (female subjects of child bearing age will be asked if they are and/or planning on becoming pregnant during the study; acceptable methods of birth control include birth control pills and barrier method)
long-term extension study of miravirsen among participants with genotype 1 chronic hepatitis c (chc) who have not responded to pegylated-interferon alpha plus ribavirin

Conditions: Chronic Hepatitis C

Summary: genotype 1 chc participants from study spc3649-207 with null response to prior pegylated-interferon alpha plus ribavirin will be enrolled into this 36-month extension study, designed to evaluate the long-term safety and efficacy after 12 weeks of miravirsen monotherapy. due to the observational nature of the study, miravirsen will not be dosed as an investigational product.


Eligibility criteria:
inclusion criteria: * participants from study spc3649-207, including those who completed the study and those who discontinued or terminated the study early for any reason, or those who opted to receive other approved therapy for the treatment of hepatitis c virus (hcv) infection exclusion criteria: * participants who have received investigational drug therapy after discontinuation, termination, or completion of study spc3649-207
international lymphatic disease and lymphedema registry

Conditions: Lymphedema

Summary: the purpose of the international lymphatic disease and lymphedema patient registry and biorepository is to collect health information in order to study the disease classification, natural history, and impact of lymphatic disease, lymphedema and related disorders and its treatments and medical outcomes.

this project represents the inauguration of an international patient registry for lymphatic diseases. this project will be completed through an affiliation with the lymphatic education \& research network, a non-profit organization whose mission is to promote research and the development of new therapies for patients with lymphatic diseases, including lymphedema. the registry will provide researchers with much-needed clinical data to study the impact of diseases of the lymphatic system, in order to develop improved treatments and find a cure for lymphatic diseases, lymphedema, and related disorders. the establishment of this initiative is a major step forward in research for direct study of groups of patients with lymphatic disease. in the future, this project will be able to be linked with a biorepository, in which tissue and blood samples derived from patients will be made available for research into human disease states. an international patient registry and tissue/cell bank program paves the way for future clinical trials of experimental drugs and therapies designed to treat lymphatic disease in human subjects.

Eligibility criteria:
inclusion criteria: * presence of lymphatic disease exclusion criteria: * none

Keywords: lymphatic disease lymphedema lymphangiomatosis lymphangiectasia protein-losing enteropathy vascular anomalies
role of lung ultrasound in assessment of recruitment maneuvers in ventilated preterms with respiratory distress syndrome and its correlation with tracheal il-6 level

Conditions: Respiratory Distress Syndrome, Newborn

Summary: this work is designed to: 1. evaluate the efficacy of lung ultrasonography in detecting opening and closing lung pressures in ventilated preterm neonates with respiratory distress syndrome. 2. determine the efficacy of lung ultrasonography in optimizing lung volume and its correlation with pulmonary inflammatory reaction as evidenced by il-6 level in tracheal aspirate.

the studied population included 44 preterm infants. anthropometric measurements, gestational age, sex, mode of delivery, maternal disease and apgar score were found to be matched in the two studied groups indicating successful randomization as seen in these balanced demographic variables between the groups. the studied population included 44 preterm infants. then they were allocated randomly to one of 2 groups in order by admission: group a: included 22 patients on whom the recruitment maneuver was applied guided by lung ultrasonography. group b: included 22 patients on whom the recruitment maneuver was not ultrasound guided. this is considered the control group. anthropometric measurements, gestational age, sex, mode of delivery, maternal disease and apgar score were found to be matched in the two studied groups indicating successful randomization as seen in these balanced demographic variables between the groups.

Eligibility criteria:
inclusion criteria: 1. gestational age ≤ 36 weeks. 2. in need for invasive mechanical ventilation for rds according to downes score . exclusion criteria: * excluded: 1. major upper or lower airway anomalies. 2. significant congenital anomalies including cardiac, abdominal or respiratory. 3. surgical cases 4. inborn errors of metabolism 5. early onset sepsis. 6. meconium aspiration syndrome. 7. hypoxic ischemic encephalopathy.
control of helicobacter pylori infection by dietary supplementation with lactobacillus reuteri

Conditions: Helicobacter Pylori Infection; Dyspepsia

Summary: helicobacter pylori colonizes approximately to 50% of the world-wide population. there is an exigency to find routes alternating to control the infection with an ample perspective but without the complications of induction of resistance to antibiotics. supplement dietetic with lactobacillus reuteri (l. reuteri) in humans takes to the colonization of epithelium gastric and this, combined with the observation of which l. reuteri has the capacity to inhibit the growth of h. pylori and its union to the gastric mucosa, indicates the potential that the native human bacteria control and influence in the colonization in humans. the acid-lactic bacteria (in particular the lactobacillus) have been studied by their effects in humans infected with h. pylori with some success to reduce the load of bacteria studies using supplements with l. reuteri as much in infected symptomatic patients as asymptomatic with h. pylori showed a clear reduction of the load of bacteria after 4 weeks of use and this was concordant with a reduction in the symptoms associated to the infection.

the objective of this study is to determine if the dietetic supplementation with a combination of the stock of l. reuteri (l. reuteri progastria) is effective to control the load of bacteria and the consequences of the infection in patients infected with h. pylori.

Eligibility criteria:
inclusion criteria: * subjects aged 18 - 65 years * infection with h. pylori defined as ∆ \> 20 ppm in the ubt test * non-ulcer dyspepsia * no earlier eradication therapy for h. pylori infection * written informed consent * stated availability throughout the entire study period * mental ability to understand and willingness to fulfil all the details of the protocol exclusion criteria: * duodenal or gastric ulcer * malt lymphoma * penicillin allergy * gastric resection (at any time) * first level relatives of gastric cancer patients * absence of gi symptoms * use of nsaids, aspirin or other anti-inflammatory drugs within 1 week (for occasional use) or 3 weeks (for chronic use) of inclusion * use of oral antibiotics and/or ppis and/or h2-antagonists during the 2 weeks prior to ingestion of the study product * pregnancy * participation in other clinical trials

Keywords: helicobacter pylori eradication therapy lactobacillus reuteri dyspeptic symptoms
dwp450 treatment in subjects with benign masseteric hypertrophy

Conditions: Benign Masseteric Hypertrophy

Summary: this study is a randomized, double-blind, placebo-controlled, phase ii optimal dose-finding study to determine the safety and efficacy of dwp450 in subjects with benign masseteric hypertrophy


Eligibility criteria:
inclusion criteria: 1. male or female subject over 18 years of age and written informed consent is obtained. 2. subject with benign masseter hypertrophy 3. subject who has bisymmetry of masseter at visual assessment. 4. subjects who meets thickness of masseter muscle by ultrasonography. 5. subjects who can and will comply with the requirements of the protocol. exclusion criteria: 1. diagnosis of myasthenia gravis, eaton-lambert syndrome, amyotrophic lateral sclerosis, or any other condition that might interfere with neuromuscular function 2. subject who got any treatment, including double jaw surgery, laser, thread treatment etc. in 12 months. 3. subject who had previously received botulinum toxin within 3 months prior to the study entry 4. subject with known hypersensitivity to botulinum toxin 5. subject who are pregnant or lactating or found pregnancy though the urine or sebum test or disagreed to avoid pregnancy during study period. 6. subjects who are not eligible for this study at the discretion of the investigator
evaluating long-term safety of efgartigimod administered intravenously and efgartigimod ph20 administered subcutaneously in children with generalized myasthenia gravis

Conditions: Generalized Myasthenia Gravis

Summary: the purpose of this trial is to evaluate the long-term safety of efgartigimod iv and efgartigimod ph20 sc administered to participants with gmg in the antecedent studies, argx-113-2006 and argx-113-2207, respectively.


Eligibility criteria:
inclusion criteria: participants are eligible to be included in the trial only if all of the following criteria apply: 1. the participant completed argx-113-2006 or argx-113-2207, defined as: 1. the participant reached end of trial in trial argx-113-2006 or end of study in argx-113-2207 and agreed to participate in the argx-113-2008 trial. 2. the participant qualifies for retreatment in trial argx-113-2006, but cannot complete a treatment period (tp) and the required intertreatment period (ip) visits within the argx-113-2006 trial's timeframe. 2. either the participant or the participant's legally authorized representative can understand the requirements of the trial and provide written informed consent/assent, and willingness and ability to comply with the trial protocol procedures. 3. contraceptive use for sexually active participants should be consistent with local regulations for those participating in clinical studies. a participant is of childbearing potential if, in the opinion of the investigator, he/she is biologically capable of having children. 1. contraceptive requirements for male participants are presented in section 10.4.2.2. 2. female adolescents of childbearing potential (faocbp) must have a negative urine pregnancy test at trial entry (tp1v1 or ip0v1) exclusion criteria: participants are excluded from the trial if any of the following criteria apply: 1. female adolescents of childbearing potential (faocbp): pregnancy or lactation, or the participant intends to become pregnant during their participation in the study. 2. discontinued early from argx-113-2006 or argx-113-2207 treatment. 3. a known hypersensitivity reaction to efgartigimod or any of its excipients. 4. any of the following medical conditions: 1. clinically significant uncontrolled chronic bacterial, viral, or fungal infection at study entry not sufficiently resolved in the investigator's opinion. 2. known autoimmune disease or any medical condition that would interfere with an accurate assessment of clinical symptoms of generalized myasthenia gravis (gmg) or put the participant at undue risk
icata asthma mechanistic study

Conditions: Asthma

Summary: the purposes of this study are to determine the effects of omalizumab on cells involved in the allergic response, to evaluate predictors of response to omalizumab, and to determine whether response to omalizumab therapy is influenced by the environment. a subset of inner-city children and adolescents currently enrolled in inner-city anti-ige therapy for asthma (a clinical trial of omalizumab) will be enrolled in this study.

immunoglobulin e (ige) is important in the development of allergic responses and may determine asthma severity. omalizumab is a man-made monoclonal antibody that directly blocks the cause of allergic reactions. there are three main objectives to this study. the first is to gain an understanding of how omalizumab affects cells involved in the immune response. the second objective is to determine whether response to omalizumab is influenced by exposure to environmental factors, including allergens and viral infections. the third objective is to determine what clinical markers can be used to determine which patients would most benefit from omalizumab therapy. this study will evaluate the immune and allergic responses of inner-city children with moderate to severe asthma who are receiving omalizumab or placebo as part of a parallel study (inner-city anti-ige therapy for asthma, icac-08, nct00377572). nasal secretions will be collected from all participants at the beginning of this study, toward the middle of the study, and with each asthma exacerbation requiring a clinical visit. some participants will participate in either the basophil or t-cell studies and associated procedures. these studies require blood collection at five study visits. sputum collection will occur at four study visits. those participants involved in the basophil studies will also undergo skin testing at three study visits.

Eligibility criteria:
inclusion criteria: * currently enrolled in icata (icac-08, nct00377572) clinical study * positive skin test to german cockroach required for participation in the basophil and t-cell studies and associated procedures * cockroach insensitive participants will serve as control groups

Keywords: immunoglobulin ige omalizumab
microcurrent versus transcutaneous electrical nerve stimulation on pressure ulcer

Conditions: Pressure Area

Summary: the purpose of the study was to evaluate which is more effective, microcurrent or transcutaneous electrical nerve stimulation, in treating pressure ulcers in elderly patients.

* pressure sores are common problems in today's health care. a pressure sore leads to physiological as well as psychological suffering for the individual affected. the cost for the society, associated with prevention and treatment of pressure sores, is considerable * furthermore, the need for this study was developed from the lack of quantitative knowledge and information in the published studies about the effect of microcurrent and transcutaneous electrical nerve stimulation in treating pressure ulcers in elderly patients. * this study will be carried out to provide guidelines about the effectiveness of microcurrent and transcutaneous electrical nerve stimulation in treating pressure ulcer and to assist in planning an ideal treatment regimen to increase healing of pressure ulcers in elderly patients.

Eligibility criteria:
inclusion criteria: subject selection was done according to the following criteria: * age range between 40 and 60 years. * male and female patients will participate in the study. * all patients enrolled in the study had their informed consent. * pressure ulcer grades were grade ii and iii. * a relative or legal tutor provided consent when participants were incapable of making decisions. * the trial complied with the ethical principles of the helsinki declaration for medical research in humans. * pressure ulcers were located in the sacral area exclusion criteria: * age less than 40 years or more than 60 years * a cardiac pacemaker or another implanted electric device. * cognitive problems or hearing loss. * pre-existing joint disorder before pressure ulcer. * patients who have co-morbidities such as diabetes mellitus, rheumatoid arthritis, hypertension, and cardiac and renal patients, * osteosynthesis implants near the ulcer, pressure ulcers in the occipital region, cancer, and osteomyelitis. * abnormal blood markers at baseline indicating limited healing potential (anemia, iron deficit, protein deficit, dehydration, non-controlled diabetes, or hypothyroidism). * allergy to the usual treatment for ulcer healing, systemic infection, and ulcer treatment with growth factor or vacuum-assisted closure in the 30 days before the trial

Keywords: micro current versus tens on pressure ulcer
radiologic results of one-stage bilateral tkr - one surgeon sequential vs. two surgeon simultaneous: a randomized controlled study

Conditions: Gonarthrosis; Primary

Summary: many surgeons and patients prefer bilateral total knee arthroplasty (tka) under one anesthesia as single-stage administration. a single-stage bilateral tka can be performed in two different ways: single-stage, two-team simultaneous bilateral tka (two surgeons bilateral tka), and single-stage, a sequential bilateral tka (single surgeon bilateral tka). the purpose of this study is to evaluate the radiological results in the single-stage bilateral tka in terms of two surgeons bilateral tka and single surgeon bilateral tka.

investigators will enroll 136 participants with primary bilateral symptomatic knee osteoarthritis that will refractory to conservative treatment who will undergo bilateral tka under single anaesthesia after 15.06.2020. investigators will include patients who were less than 75 years old, with no history of malignancy, without severe extra-articular deformities, and without the systemic inflammatory disease, severe cardiac insufficiency, and morbid obesity (\>40 kg/m2 or 35 or more and experiencing obesity-related health conditions). an informed consent form will be obtained from all patients.

Eligibility criteria:
inclusion criteria: primary bilateral knee osteoarthritis with refractory to conservative treatment patients who accept participation in the research and the randomization exclusion criteria: no history of malignancy less than 75 years old without severe extra-articular deformities severe cardiac insufficiency and morbid obesity without systemic inflammatory diseases
the effects of milk and banana as a night meal to primary insomnia on sleep quality, bdnf and appetite mechanism

Conditions: Primary Insomnia

Summary: the aim of this study to determine the impact of banana and milk on sleep and appetite

sleep is one of the main components of the continuity of circadian rhythm. it restores energy and enhancement, memory. sleep disturbances and short sleep duration are important risk factors for many diseases. nutrition is one of the main determinants of health status in many diseases related to inflammation. especially the night meal, known as the foods consumed before bedtime, has a strong effect on sleep. although there are methodological differences, most studies show that unhealthy eating habits are associated with short sleep duration. it is thought that consuming foods with high tryptophan and melatonin content can reduce sleep problems. this study will give a chance to observe the effects of nutrients on sleep and appetite mechanisms.

Eligibility criteria:
inclusion criteria: * applying to the sleep polyclinic, * 18-45 years old, * body mass index (bmi) between 18.5-25 kg/m2, * male and female patients diagnosed with primary sleep disorder for the first time exclusion criteria: * individuals with any psychiatric illness, * those who use cigarettes, alcohol, drugs or sedative drugs, * individuals with any chronic disease (diabetes, etc.), * pregnant and/or lactating * individuals with lactose intolerance, * athletes, * individuals who are allergic to bananas * individuals with lactose intolerance or milk intolerance

Keywords: diet food bdnf appetite